Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates

Cancer-related bone pain is experienced by patients with primary bone tumours such as myeloma and osteosarcoma, but is more commonly seen in patients with malignant tumours that have metastasised to bone. Bone pain is one of the most common and severe forms of pain associated with breast, prostate and lung cancer, yet little is known about the underlying mechanisms responsible for the pain. Cancer patients identify bone pain as the most disruptive cancer-related event in terms oftheir quality of life and daily functioning, and it is also associated with increased incidence of morbidity, depression, and anxiety.Part of the Oxford Pain Management Library, this volume summarises the latest evidence-based and practical information on the management of cancer-related bone pain. Chapters cover the pathophysiology and clinical features of bone pain, general principles of management and the use of opioids and other agents. It will be an invaluable reference for all health care professionals involved in the management of patients with bone pain from various disciplines including palliative care,anaesthetics, oncology and general practice.

Cancer-related bone pain is experienced by patients with primary bone tumours such as myeloma and osteosarcoma, but is more commonly seen in patients with malignant tumours that have metastasised to bone. Bone pain is one of the most common and severe forms of pain associated with breast, prostate and lung cancer, yet little is known about the underlying mechanisms responsible for the pain. Cancer patients identify bone pain as the most disruptive cancer-related event in terms of their quality of life and daily functioning, and it is also associated with increased incidence of morbidity, depression, and anxiety. Part of the Oxford Pain Management Library, this volume summarises the latest evidence-based and practical information on the management of cancer-related bone pain. Chapters cover the pathophysiology and clinical features of bone pain, general principles of management and the use of opioids and other agents. It will be an invaluable reference for all health care professionals involved in the management of patients with bone pain from various disciplines including palliative care, anaesthetics, oncology and general practice.

The epidemiological and clinical importance of bone metastasis has long been recognized, but the past decade has seen an explosion in the fields of bone biology and bone cancer research. This period of time has been marked by a number of key discoveries that have led to the opening up of entirely new areas for investigation as well as new therapies which combine surgery and biological therapeutic approaches.Bone is a common site of cancer metastases - cancer cells commonly develop in bone and spread to other organ systems through the bloodstream. For example, the incidence of bone metastases in breast and prostate cancers is 70%, whereas it is only 30 to 40% in metastatic lung cancer. In clinical terms, bone metastases have substantial negative effects on a patient's quality of life and are a main cause of patient mortality. Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for the medical and cancer research communities. This book provides, all in one resource, the most recent data on bone cancer development (cellular and molecular mechanisms), genomic and proteomic analyses, clinical analyses (histopathology, imaging, pain monitoring), as well as new therapeutic approaches and clinical trials for primary bone tumors and bone metastases. Feature Presents a comprehensive, translational source for all aspects of bone cancer in one reference work Bone cancer experts (from all areas of research and practice) take readers from the bench research (cellular and molecular mechanism), through genomic and proteomic analysis, all the way to clinical analysis (histopathology and imaging) and new therapeutic approaches. Clear presentation by bone biologists of the cellular and molecular mechanisms underlying bone tumors and bone cancer metastasis as well as the genomic and proteomic assays used in detecting cancer within given organ systems Clear presentation by oncologists and radiologists of how histopathology, imaging, and pain monitoring can lead to new therapeutic approaches Benefit Saves researchers and clinicians time in quickly accessing the very latest details on a broad range of bone cancer issues, as opposed to searching through thousands of journal articles. Provides a common language for cancer researchers, bone biologists, oncologists, and radiologists to discuss bone tumors and how bone cancer metastases affects each major organ system Correct diagnosis (and therefore correct treatment) of cancer depends on a strong understanding of the molecular basis for the disease – both oncologists and radiologists will benefit Bone biologists will gain insight into how clinical observations and practices can feed back into the research cycle and will, therefore, be able to develop more targeted genomic and proteomic assays

Bone Cancer, Second Edition comprehensively investigates key discoveries in the field of bone biology over the last five years that have led to the development of entirely new areas for investigation, such as therapies which combine surgery and biological approaches. The Second Edition expands on the original overview of bone cancer development (physiology and pathophysiology), with key chapters from the first edition, and offers numerous new chapters describing the new concepts of bone cancer biology and therapy, for both primary bone tumors as well as bone metastases. Each chapter has been written by internationally recognized specialists on the bone cancer microenvironment, bone metastases, osteoclast biology in bone cancer, proteomics, bone niche, circulating tumor cells, and clinical trials. Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for everyone within the medical and cancer research communities. Bone Cancer continues to offer the only translational reference to cover all aspects of primary bone cancer and bone metastases – from bench to bedside: development (cellular and molecular mechanisms), genomic and proteomic analyses, clinical analyses (histopathology, imaging, pain monitoring), as well as new therapeutic approaches and clinical trials for primary bone tumors and bone metastases. Presents a comprehensive, translational source for all aspects of primary bone cancer and bone metastases in one reference work Provides a common language for cancer researchers, bone biologists, oncologists, and radiologists to discuss bone tumors and how bone cancer metastases affects each major organ system Offers insights to research clinicians (oncologists and radiologists) into understanding the molecular basis of bone cancer, leading to more well-informed diagnoses and treatment of tumors and metastases Offers insights to bone biologists into how clinical observations and practices can feed back into the research cycle and, therefore, can contribute to the development of more targeted genomic and proteomic assays